October 10, 2005. Antigenics reported good preliminary results from a Phase III trial of its treatment for metastatic melanoma, though only among a subset of the patients, Alpharma won FDA permission to begin a Phase II trial of its extended-release opioid, an endovascular device company, ev3, offered to buy the 29.8% of Micro Therapeutics it does not already own,and Genentech made its Q3 financial report, which was about 50% higher than last year and beat analysts’ expectations. The Centient Biotech 200 was 7 points lower at the end of trading, closing at just under 3637, a drop of .19%. More details...
